目的 探究注射用盐酸表柔比星联合氟尿嘧啶注射液治疗晚期结直肠癌的临床疗效。方法 选取2016年9月-2018年9月十堰市人民医院（湖北医药学院附属人民医院）收治的90例晚期结直肠癌患者为研究对象，所有患者随机分为对照组（50例）和治疗组（40例）。对照组第1~5天静脉滴注氟尿嘧啶注射液400 mg/m²。治疗组在对照组治疗的基础上第1天静脉滴注注射用盐酸表柔比星120 mg/m²。每21天为1个周期，两组患者均治疗1个周期。观察两组的临床疗效，比较两组的生活质量、血清肿瘤标志物水平、不良反应。结果 治疗后，对照组和治疗组的客观缓解率（ORR）分别为58.0%、72.5%，疾病控制率（DCR）分别为78.0%、85.0%，两组比较差异有统计学意义（P<0.05）。治疗后，对照组和治疗组的生活质量改善率分别为36.0%、62.5%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者糖蛋白199（CA199）、癌胚抗原（CEA）水平显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组患者血清肿瘤标志物水平明显低于对照组，两组比较差异有统计学意义（P<0.05）。对照组和治疗组白细胞减少发生率分别为30.0%、45.0%，血小板减少发生率分别为30.0%、52.5%，两组比较差异有统计学意义（P<0.05）。结论 表柔比星联合氟尿嘧啶注射液治疗晚期结直肠癌具有良好的临床疗效，可改善生活质量，降低血清肿瘤标志物水平，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Epirubicin Hydrochloride for injection combined with Fluorouracil Injection in treatment of advanced colorectal cancer. Methods Patients (90 cases) with advanced colorectal cancer in Shiyan People's Hospital (Affiliated People's Hospital of Hubei Medical College) from September 2016 to September 2018 were randomly divided into the control group (50 cases) and the treatment group (40 cases). Patients in the control group were iv administered with Fluorouracil Injection on the first day to fifth day 400 mg/m². Patients in the treatment group were iv administered with Epirubicin Hydrochloride for injection on the basis of the control group on the first day 120 mg/m². Every 21 days iwas a cycle, and patients in two groups were treated for 1 cycle. After treatment, the clinical efficacies were evaluated, and quality of life, serum level of tumor markers, and adverse reactions in two groups were compared. Results After treatment, the ORR in the control and treatment groups were 58.0% and 72.5%, respectively, and the DCR in the control and treatment groups were 78.0% and 85.0%, respectively, and there was difference between two groups (P<0.05). After treatment, the improvement rate of quality of life in the control and treatment groups were 36.0% and 62.5%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of CA199 and CEA in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum level of tumor markers in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the incidence of leukocytopenia in the control and treatment groups were 30.0% and 45.0%, respectively, the incidence of thrombocytopenia in the control and treatment groups were 30.0% and 52.5%, respectively, and there was difference between two groups (P<0.05). Conclusion Epirubicin Hydrochloride for injection combined with Fluorouracil Injection has clinical curative effect in treatment of advanced colorectal cancer, can improve the quality of life, and reduce the serum level of tumor markers, which has a certain clinical application value.

湖北省科委资助项目（982P1511）